Dr. Petros Kechagioglou

PostDoc

Petros obtained his BSc in Chemistry and MSc in Biochemistry at the Aristotle University of Thessaloniki, Greece. During his PhD, he focused on the possible association between the progress of breast cancer and the role of proteins involved in the PI3K/Akt pathway. Following his PhD studies, he worked as a postdoctoral researcher at the University of Saskatchewan, Canada. His research activity was to study the effects of the antacid proton pump inhibitors on tumor progression and metastatic dissemination in oral cancer.

In 2021, he became a member of the Research Group of Prof. Dr. Krishnaraj Rajalingam. His research objective is to evaluate the efficacy of kinase inhibitors in breast cancer, and to consolidate their mechanism of action by identifying other targets engaged by those compounds.

Prefessional Experience

• 2021 - present: Postdoctoral Researcher, Research Group of Prof. Dr. Krishnaraj Rajalingam, CBU, JGU Mainz, Germany

• 2017 - 2019: Postdoctoral Researcher, Department of Surgery, University of Saskatchewan, Canada

• 2016 - 2017: Research Fellow, Department of Chemistry, Aristotle University of Thessaloniki, Greece

Education

• 2011 - 2014: PhD candidate in Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, Greece

• 2009 - 2011: Master of Science in Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, Greece

• 2004 - 2009: Bachelor of Science in Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, Greece

Publications

• Riegel, K., P. Vijayarangakannan, P. Kechagioglou, K. Bogucka, and K. Rajalingam, Recent advances in targeting protein kinases and pseudokinases in cancer biology. Frontiers in Cell and Developmental Biology, 2022. 10.

• Petros Kechagioglou, Debomita Chakraborty, Camille Dupont, Hajime Yurugi, Ute Distler, Stefan Tenzer, Alexey Chernobrovkin, Kristina Riegel, Julianne Mooz, Mahil Lamber, Volker Dötsch, Stephen Cosenza, Steven Fruchtman, Krishnaraj Rajalingam. Narazaciclib’s differential targets and kinase inhibitory activity contribute to the enhanced inhibition of tumor growth in preclinical models [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO5-24-01

• Petros Kechagioglou, Camille Dupont, Hajime Yurugi, Alexey Chernobrovkin, Rossana Romero, Rebecca Tweedell, Thirumala-Devi Kanneganti, Stephen Cosenza, Steven M. Fruchtman, Krishnaraj Rajalingam. Rigosertib promotes anti-tumor activity of cancer cells via CETSA revealed novel targets and activates NLRP3-dependent inflammatory responses [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2033.

• Papi RM, Tasioulis KS, Kechagioglou PV, Papaioannou MA, Andriotis EG, Kyriakidis DA. Carbon Nanotube-Mediated Delivery of PTEN Variants: In Vitro Antitumor Activity in Breast Cancer Cells. Molecules. 2024 Jun 11;29(12):2785. doi: 10.3390/molecules29122785. PMID: 38930850; PMCID: PMC11206347.